• J3/31 A-3 Khiri Extention Malviya Nagar, New Delhi-17
  • macnispharma@gmail.com
  • Working Hours - Mon - Fri: 9:30 - 18:30

RABENIS

RABENIS

RABENIS 20

For the use only of a Registered Medical Practitioner or Hospital or a Laboratory

Abbreviated Prescribing information for RABENIS 20

(Rabeprazole sodium 20 mg tablets I.P.)

[Please refer the complete prescribing information available at www.macnispharma.com ]

PHARMACOLOGICAL PROPERTIES: Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) which suppress gastric acid secretion by inhibiting the gastric H+, K+ ATPase at the secretory surface of the gastric parietal cell.

INDICATION: For Gastroesophageal reflux disease (GERD), duodenal ulcer and Zollinger Ellison syndrome.    DOSAGE AND ADMINISTRATION: Rabenis tablets should be swallowed whole and not be chewed, crushed, or split. Healing of erosive or ulcerative GERD: 20 mg once daily for 4 to 8 weeks. Maintenance of healing of erosive or ulcerative GERD: 20 mg once daily (reported studies for 12 months). Treatment of symptomatic GERD in adults: 20 mg once daily for 4 weeks.  Healing of duodenal ulcers: 20 mg once daily after morning meal for up to 4 weeks. Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence (three drug regimen- rabeprazole 20 mg, amoxicillin 1000 mg and clarithromycin 500 mg): All three medications should be taken twice daily with morning and evening meals for 7 days. Treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome: Starting dose 60 mg once daily then adjust to patient needs. Treatment of symptomatic GERD in adolescents 12 years of age and older:  20 mg once daily for up to 8 weeks.

CONTRAINDICATION: Patients with known hypersensitivity to rabeprazole sodium, substituted benzimidazoles or to any excipient used in the formulation.

WARNINGS & PRECAUTIONS: Symptomatic response to therapy with rabeprazole does not preclude the presence of gastric malignancy. Monitor for increases in INR and prothrombin time when used with warfarin. Risk of acute interstitial nephritis and Clostridium difficile associated diarrhoea. On prolonged therapy risk of cyanocobalamin (vitamin B-12) Deficiency, bone fracture and hypomagnesemia.

DRUG INTERACTIONS: Interact with warfarin, cyclosporine, clarithromycin, ketoconazole, iron salts, digoxin, mycophenolate mofetil, atazanavir and methotrexate when used concomitantly.

ADVERSE REACTIONS: Pain, pharyngitis, flatulence, infection and constipation. Abdominal pain, diarrhoea, nausea and headache. Post-marketing experience: Sudden death, coma, jaundice, rhabdomyolysis, anaphylaxis, severe dermatologic reactions, including toxic epidermal necrolysis (some fatal) and Stevens-Johnson syndrome and interstitial pneumonia.

MARKETED BY:

MACNIS PHARMACEUTICALS

J3/31 A-3,3rd Floor,Khiri Extension.

Malviya Nagar,New Delhi-17


Visit us at: www.macnispharma.com

Reach us at: info@macnispharma.com